SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

What Was Tested

The trial (phase 2) is built around Semaglutide.

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells mediated by autoreactive T lymphocytes, resulting in absolute insulin deficiency.

It had four arms (groups): Shingrix + Semaglutide Placebo (active comparator), Semaglutide + RZV Placebo (active comparator), Shingrix + Semaglutide (Combination (experimental) and Double placebo (placebo comparator).

The registry classes the interventions as drug.

More on the Plan

The immune pathogenesis of T1D involves a failure of central and peripheral immune tolerance, with autoreactive CD4+ and CD8+ T cells targeting beta-cell autoantigens including GAD65, IA-2, and ZnT8.

The window between seroconversion and overt hyperglycemia - and particularly the honeymoon phase immediately following diagnosis - represents an optimal period for immune intervention while sufficient beta-cell mass persists.

The Recombinant Zoster Vaccine (RZV; Shingrix) contains the AS01B adjuvant system (MPL + QS-21 in a liposomal formulation), which potently activates plasmacytoid dendritic cells and promotes generation of antigen-specific and bystander Tregs.

Critically, RZV is already FDA-approved with an established safety profile, enabling accelerated clinical translation.

Who Took Part

The registry lists 240 planned participants were the target.

It was open to people of any sex aged from 18 years up to 50 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Diagnosis of Type 1 Diabetes (T1D) according to American Diabetes Association (ADA) criteria. Age 18 to 50 years (inclusive) at the time of screening. Randomization within 100 days of the first insulin injection. Presence of at least one T1D-related autoantibody (GADA, IA-2A, ZnT8A, or ICA). Willingness to comply with intensive insulin therapy and glucose monitoring.

The full record lists 7 inclusion and 9 exclusion criteria; among the exclusions: history of diabetic ketoacidosis (dka) within 4 weeks of screening; prior use of any immunotherapy or investigational agents for t1d; current or prior use of glp-1 receptor agonists, dpp-4 inhibitors, or sglt2 inhibitors.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2027-01-01 with completion listed for 2028-01-31.

It ran at 1 site in Saudi Arabia.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT) (time frame: Baseline and 12 months).

It also tracked 1 secondary outcome, for example Glycated Hemoglobin (HbA1c) levels.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 240 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.